髓过氧化物酶指数在57例急性冠状动脉综合征患者的临床应用

Clinical application of myeloperoxidase index in 57 cases of acute coronary syndrome

目的研究急性冠状动脉综合征(ACS)患者血液中性粒细胞髓过氧化物酶活性指数(MPXI)的变化及临床应用。方法选择2011年5～8月该院收治的ACS患者57例。其中,不稳定型心绞痛(UAP)20例为UAP组。非ST段抬高心肌梗死(NSTEMI)20例为NSTEMI组。ST段抬高型心肌梗死(STEMI)17例为STEMI组。选取同期该院体检中心健康体检者20例为对照组。比较4组MPXI、心肌肌钙蛋白I(cTnI)等指标的结果。结果对照组、UAP组、NSTEMI组血液MPXI、白细胞(WBC)、中性粒细胞(NEUT)、中性粒细胞比值(NEUT%)低于STEMI组(P<0.05)。结论常规血细胞分析能快捷方便检测出血液MPXI结果,可作为ACS疾病粥样斑块不稳定性的标志物之一,有利于ACS疾病的早期诊断与监测。

Objective To study the change of neutrophil myeloperoxidase index（MPXD in acute coronary syndrome（ACS） and its clinical application. Methods 57 cases of MPXI from May to August 2011 were selected and divided into the unstable angina pectoris（UAP） group（20 cases）,non-ST-elevation myocardial infarction（NSTEMI） group（20 cases） and the ST-elevation myocar- dial infarction（STEMI） group（17 cases）. Contemporaneous 20 individuals with healthy physical examination were selected as con- trols. The indexes such as MPXI and cardiac troponin I（cTnI） were determined and analyzed among 4 groups. Results MPXI, WBC, NEUT and NEUT% in the control, UAP and NSTEMI groups were significantly lower than those in the STEMI group（P〈0.05）. Conclusion Routine blood cells analysis may detect MPXI rapidly and conveniently,MPXI may be used as one of markers for the plaque instability in ACS and is conducive to its early diagnosis and monitoring.